M&A Deal Summary |
|
|---|---|
| Date | 2013-11-07 |
| Target | Santarus |
| Sector | Life Science |
| Buyer(s) | Salix Pharmaceuticals |
| Deal Type | Add-on Acquisition |
| Deal Value | 2.6B USD |
| Advisor(s) | Stifel (Financial) Latham & Watkins (Legal) |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1989 |
| Sector | Life Science |
| Revenue | 933M USD (2013) |
Salix Pharmaceuticals Ltd. is a developer and marketer of prescription pharmaceutical products and medical devices for the prevention and treatment of gastrointestinal diseases. Salix's strategy is to in-license late-stage or marketed proprietary therapeutic products, complete any required development and regulatory submission of these products, and market them through Salix's gastroenterology specialty sales and marketing team.
| DEAL STATS | # |
|---|---|
| Overall | 4 of 4 |
| Sector: Life Science M&A | 2 of 2 |
| Type: Add-on Acquisition M&A Deals | 3 of 3 |
| State: California M&A | 1 of 1 |
| Country: United States M&A | 3 of 3 |
| Year: 2013 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2011-11-08 |
Oceana Therapeutics
Edison, New Jersey, United States Oceana Therapeutics, Inc., a privately-held provider of gastroenterology and urology therapeutics. |
Buy | - |
